Clinical trials: Patients With Advanced Solid Tumors
Solid Cancers
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
This global, multicenter, open-label study will evaluate the safety and tolerability of atezolizumab in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies.
- Trial name
- NCT02174172
- Testing
- Atezolizumab, Bevacizumab, Interferon alfa-2b
- Where
- 9 sites in United States, Netherlands
- Volunteers
- 158 people
- Sponsor
- Hoffmann-La Roche
Advanced Malignancy, Advanced Solid Cancers
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Cancers, Metastatic Solid Tumors
- Trial name
- NCT07238075
- Testing
- ADCX-020
- Where
- 9 sites in Australia, Spain
- Volunteers
- 290 people
- Sponsor
- Adcytherix SAS
Neoplasms
A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors
To evaluate safety and tolerability of PF-00299804 in Japanese patients with advanced malignant solid tumors at doses up to the clinically recommended phase 2 dose in non-Japanese studies.
- Trial name
- NCT00783328
- Testing
- PF-00299804
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Pfizer
Advanced Solid Tumors
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.
- Trial name
- NCT07093970
- Testing
- MRG006A
- Where
- 2 sites in China
- Volunteers
- 343 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Urothelial Carcinoma, Bladder Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia
- Trial name
- PRESERVE3 (NCT04887831)
- Testing
- Trilaciclib, Gemcitabine, Cisplatin
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 92 people
- Sponsor
- G1 Therapeutics, Inc.
Solid Malignancies
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors.
- Trial name
- NCT00033202
- Testing
- Gimatecan® (ST-1481)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sigma-Tau Research, Inc.
Neoplasm Malignant
A Study of SAR428926 in Patients With Advanced Solid Tumors
Primary Objectives: To determine the maximum tolerated dose (MTD) of SAR428926 when administered as a single agent in patients with advanced solid tumors.
- Trial name
- NCT02575781
- Testing
- SAR428926
- Where
- 3 sites in Denmark, France and 1 more
- Volunteers
- 34 people
- Sponsor
- Sanofi
Advanced Solid Neoplasms, Lymphoma Neoplasms
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of [14C]-TAK-659…
- Trial name
- NCT03338881
- Testing
- [14C]-TAK-659, TAK-659
- Sponsor
- Calithera Biosciences, Inc
Neoplasm Malignant
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Primary Objectives: To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic impairment To determine the pharmacokinetics (PKs) of…
- Trial name
- NCT01140607
- Testing
- Cabazitaxel (XRP6258)
- Where
- 14 sites in United States
- Volunteers
- 56 people
- Sponsor
- Sanofi
Solid Tumors
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body
This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful or no treatment exists can take part. This study tests a medicine called BI 907828.
- Trial name
- NCT05613036
- Testing
- [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1), [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2), BI 907828
- Where
- Hungary
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Advanced/Metastatic Solid Tumors
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in…
- Trial name
- NCT04182516
- Testing
- NMS-03305293
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 52 people
- Sponsor
- Nerviano Medical Sciences
Patients with Advanced Solid Tumors
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.
- Trial name
- NCT05970016
- Testing
- TCC1727 tablet（1）, TCC1727 tablet（2）
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Neoplasms
A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors
This open-label, multi-center, dose-escalation study will evaluate the safety, pharmacokinetics, and therapeutic activity of RO6895882 in participants with Carcinoembryonic Antigen (CEA)-positive solid tumors who have progressed…
- Trial name
- NCT02004106
- Testing
- RO6895882
- Where
- 10 sites in United States, Denmark and 6 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer
The main objective of this study is to determine the maximum tolerated dose (MTD) of Oral Paclitaxel. Eligible subjects of this study are patients with histologically or cytologically confirmed malignant solid tumor refractory to…
- Trial name
- NCT01491204
- Testing
- Paclitaxel+HM30181
- Volunteers
- 25 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Advanced Solid Tumors, Hematologic Malignancies
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing…
- Trial name
- SPI-FOL-102 (NCT07036133)
- Testing
- Pralatrexate Injection
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acrotech Biopharma Inc.
Advanced Solid Tumor
PTX-35 in Patients With Advanced Solid Tumors
A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care
- Trial name
- NCT04430348
- Testing
- PTX-35
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pelican Therapeutics, Inc.
Solid Tumor
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with…
- Trial name
- NCT06619587
- Testing
- Phase I Arm A, Phase I Arm B
- Where
- 49 sites in United States, Australia and 10 more
- Volunteers
- 410 people
- Sponsor
- Genentech, Inc.
Advanced Malignant Solid Tumor
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to…
- Trial name
- NCT05477849
- Testing
- Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Virogin Biotech Co., Ltd.
Solid Tumor
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
This is an open-label, multi-center study to evaluate the efficacy and safety of SHR-1701 in combination with famitinib in subjects with metastatic or locally advanced solid tumor.
- Trial name
- NCT04679038
- Testing
- SHR-1701, Famitinib
- Where
- 16 sites in China
- Volunteers
- 222 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors
- Trial name
- WEE1 (NCT04768868)
- Testing
- IMP7068
- Where
- 16 sites in United States, China and 1 more
- Volunteers
- 350 people
- Sponsor
- Impact Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.